litlas
Log inCreate account

Margarita Majem

Active 2009–2025

118
Papers
22,497
Citations
54
h-index
106
i10-index

Citations

Citations per year for Margarita Majem1971: 3 citations2001: 2 citations2005: 1 citations2007: 1 citations2008: 2 citations2009: 5 citations2010: 41 citations2011: 69 citations2012: 47 citations2013: 64 citations2014: 43 citations2015: 77 citations2016: 139 citations2017: 254 citations2018: 296 citations2019: 871 citations2020: 899 citations2021: 1,027 citations2022: 896 citations2023: 833 citations2024: 1,535 citations2025: 931 citations2026: 13 citations1972–2000: no citations, so these years are not shown2002–2004: no citations, so these years are not shown2006: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,475 citing papers, 20.5% of this breakdownChina: 1,921 citing papers, 15.9% of this breakdownJapan: 768 citing papers, 6.4% of this breakdownItaly: 750 citing papers, 6.2% of this breakdownFrance: 591 citing papers, 4.9% of this breakdownSpain: 589 citing papers, 4.9% of this breakdownUnited Kingdom: 534 citing papers, 4.4% of this breakdownGermany: 440 citing papers, 3.7% of this breakdownCanada: 410 citing papers, 3.4% of this breakdownSouth Korea: 371 citing papers, 3.1% of this breakdownNetherlands: 302 citing papers, 2.5% of this breakdownAustralia: 260 citing papers, 2.2% of this breakdown
0%20.5%Other 21.9%

Institutions

Fields

  • Medicine83.5%
  • Biochemistry, Genetics and Molecular Biology11.6%
  • Immunology and Microbiology3%
  • Engineering0.4%
  • Computer Science0.2%
  • Chemistry0.2%
  • Other1.1%

Topics

  • Cancer Immunotherapy and Biomarkers16.9%
  • Lung Cancer Treatments and Mutations15.1%
  • Lung Cancer Research Studies8.4%
  • Lung Cancer Diagnosis and Treatment7.4%
  • Cancer Genomics and Diagnostics3.9%
  • Immunotherapy and Immune Responses3%
  • Other45.3%

Coauthors

All papers

Open in search
  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

    Authors: Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon - The Lancet 2015 cited by 6,537

  2. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

    Authors: Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Shugeng Gao, Ke‐Neng Chen, Christophe Dooms, Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Silvia Novello, Jing Yang, Steven M. Keller, Ayman Samkari, Jonathan Spicer - New England Journal of Medicine 2023 cited by 1,030

  3. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer

    Authors: Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst - New England Journal of Medicine 2020 cited by 1,756

  4. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    Authors: Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip, Ippokratis Korantzis, Kadoaki Ohashi, Margarita Majem, Óscar Juan, Sabin Handzhiev, Hiroki Izumi, Jong Seok Lee, Rafał Dziadziuszko, Jürgen Wolf, Fiona Blackhall, Martin Reck, Jean Bustamante Alvarez, Horst-Dieter Hummel, Anne‐Marie C. Dingemans, Jacob Sands, Hiroaki Akamatsu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Hossein Borghaei, Melissa L. Johnson, Shuang Huang, Sujoy Mukherjee, Mukul Minocha, Tony Jiang, Pablo Martínez, Erik S. Anderson, Luis Paz‐Ares - New England Journal of Medicine 2023 cited by 482

  5. Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC

    Authors: Masahiro Tsuboi, Roy S. Herbst, Thomas John, Terufumi Kato, Margarita Majem, Christian Grohé, Jie Wang, Jonathan W. Goldman, Shun Lü, Wu‐Chou Su, Filippo de Marinis, Frances A. Shepherd, Ki Hyeong Lee, Nhieu Thi Le, Arunee Dechaphunkul, Dariusz M. Kowalski, Lynne Poole, Ana Bolanos, Yuri Rukazenkov, Yi‐Long Wu - New England Journal of Medicine 2023 cited by 612

  6. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal‐Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Marta Casarrubios, Clara Salas, Edwin R. Parra, Ignacio I. Wistuba, Virginia Calvo, Raquel Laza‐Briviesca, Atocha Romero, Bartomeu Massutí, Alberto Cruz‐Bermúdez - The Lancet Oncology 2020 cited by 828

  7. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    Authors: Caicun Zhou, Kejing Tang, Byoung Chul Cho, Baogang Liu, Luis Paz‐Ares, Susanna Y. Cheng, Satoru Kitazono, Muthukkumaran Thiagarajan, Jonathan W. Goldman, Joshua K. Sabari, Rachel E. Sanborn, Aaron S. Mansfield, Jen‐Yu Hung, Michael Boyer, Sanjay Popat, Josiane Mourão Dias, Enriqueta Felip, Margarita Majem, Mahmut Gümüş, Sang‐We Kim, Akira Ono, John Xie, Archan Bhattacharya, Trishala Agrawal, S. Martin Shreeve, Roland E. Knoblauch, Keunchil Park, Nicolas Girard - New England Journal of Medicine 2023 cited by 347

  8. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

    Authors: Roy S. Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, Isabelle Monnet, Alfredo Sanchez-Hernandez, Shaker Dakhil, D. Ross Camidge, Leanne Winzer, Yee Soo-Hoo, Zachary A. Cooper, Rakesh Kumar, John Bothos, Charu Aggarwal, Alex Martinez-Marti - Journal of Clinical Oncology 2022 cited by 287

  9. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

    Authors: Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal, Amelia Insa, M.R. García-Campelo, J. Casal Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Virginia Calvo, Javier Martín-López, Francisco Garcia‐García, Marta Casarrubios, Fernando Franco, Estela Sánchez‐Herrero, Bartomeu Massutí, Alberto Cruz‐Bermúdez, Atocha Romero - Journal of Clinical Oncology 2022 cited by 335

  10. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

    Authors: Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, Alexander Todd, Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam - Nature Communications 2023 cited by 239

  11. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

    Authors: Roy S. Herbst, Yi‐Long Wu, Thomas John, Christian Grohé, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Chong‐Jen Yu, Hữu Vĩnh Vũ, Shun Lü, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi - Journal of Clinical Oncology 2023 cited by 389

  12. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

    Authors: Fiona Blackhall, Kevin Jao, Laurent Greillier, Byoung Chul Cho, Konstantin Penkov, Noemı́ Reguart, Margarita Majem, Kristiaan Nackaerts, Konstantinos Syrigos, Karin Holmskov Hansen, Wolfgang Schuette, Jeremy Cetnar, Federico Cappuzzo, Isamu Okamoto, Mustafa Erman, Seppo W. Langer, Terufumi Kato, Harry J.M. Groen, Zhaowen Sun, Yan Luo, Poonam Tanwani, L. Caffrey, Philip Komarnitsky, Niels Reinmuth - Journal of Thoracic Oncology 2021 cited by 258

  13. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

    Authors: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, Radj Gervais, José Luis Perez‐Gracia, Ji‐Youn Han, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Matthew A. Gubens, Michael Boyer, Wu‐Chou Su, Ayman Samkari, Erin Jensen, Julie Kobie, Bilal Piperdi, Paul Baas - Journal of Thoracic Oncology 2021 cited by 312

  14. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

    Authors: Rafael Rosell, Teresa Morán, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo López-Vivanco, Dolores Isla, Mariano Provencio, Amelia Insa, Bartomeu Massutí, J.L. González-Larriba, Luis Paz‐Ares, Isabel Bover, Rosario García‐Campelo, Miguel Ángel Moreno, Sílvia Catot, Christian Rolfo, Noemı́ Reguart, Ramón Palmero, José Miguel Sánchez, Roman Bastus, Clara Mayo, Jordi Bertran-Alamillo, Miguel Ángel Molina‐Vila, José Javier Sánchez, Miquel Tarón - New England Journal of Medicine 2009 cited by 2,377

  15. LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

    Authors: J.D. Spicer, Shugeng Gao, Moïshe Liberman, Terufumi Kato, M. Tsuboi, SH Lee, K-N. Chen, Christophe Dooms, Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, M.C. Garassino, Delvys Rodríguez‐Abreu, Jamie E. Chaft, S. Novello, James Chih‐Hsin Yang, S.M. Keller, Ayman Samkari, Heather A. Wakelee - Annals of Oncology 2023 cited by 75

  16. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

    Authors: Glenwood Goss, Chun‐Ming Tsai, Frances A. Shepherd, Lyudmila Bazhenova, Jong Seok Lee, Gee‐Chen Chang, Lucio Crinò, Miyako Satouchi, Quincy S. Chu, Toyoaki Hida, Ji‐Youn Han, Óscar Juan, Frank Dunphy, Makoto Nishio, Jin‐Hyoung Kang, Margarita Majem, Helen Mann, Mireille Cantarini, Serban Ghiorghiu, Tetsuya Mitsudomi - The Lancet Oncology 2016 cited by 643

  17. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

    Authors: Suresh S. Ramalingam, Yi Cheng, C. Zhou, Y. Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, A. Todd, Aleksandra Markovets, J. Carl Barrett, Juliann Chmielecki, Jhanelle E. Gray - Annals of Oncology 2018 cited by 355

  18. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Ke‐Neng Chen, Christophe Dooms, Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, Delvys Rodríguez‐Abreu, Jamie E. Chaft, Silvia Novello, Jing Yang, Ashwini Arunachalam, Steven M. Keller, Ayman Samkari, Shugeng Gao, Shugeng Gao, Sergey Afanasyev, Samreen Ahmed, Todd Alekshun, Gustavo Alves, Ian Anderson, Luiz Henrique Araujo, Alexander Arkhipov, Arvind Arora, Jie Bai, Paul Begin, Aleksandr Belonogov, Henri Berard, Radu Berceanu-Ion, Reyes Bernabe Caro, Igor Bondarenko, Reiner Bonnet, Joaquim Bosch Barrera, Carlos Brocca, Maciej Bryl, Alessandra Bulotta, Olivier Bylicki, Antonio Calles Blanco, Enric Carcereny, Leticia Carvalho, Cristina Cebotaru, Jamie Chaft, Veena Charu, Fabio Chaves, Jun Chen, Ke-Neng Chen, Haiquan Chen, Qixun Chen, Kevin Chen, Chi-Lu Chiang, Chao-Hua Chiu, Saulius Cicenas, Elena Ciubotaru, Tudor Ciuleanu, Ioana Ciurescu, Patrick Cobb, Corlia Coetzee, Dearbhaile Collins, Diego Cortinovis, Kimberly Costas, Dan Costin, Eduardo Henrique Cronemberger, Raymund Cuevo, Sinead Cuffe, Pedro Rafael Martins De Marchi, Tadeu de Paiva Junior, Angelo Delmonte, Ingel Demedts, Koenraad Deschepper, Josiane Dias, Christophe Dooms, Boris Duchemann, Carolina Dutra, Herbert Duvivier, Ekkehard Eigendorff, Vinicius Ernani, Martin Faehling, Luiza Faria, Alexander Fedenko, Hiran Fernando, Roberto Ferrara, Vittorio Ferrari, Gene Finley, Peter Fix, Marcos Flores, Samuel Fourie, Fabio Franke, Klaus-Peter Frohling, Muhammad Furqan, Cristian Gal, Robert Galamaga, Doina Ganea, Apar Kishor Ganti, Shugeng Gao and 176 more - The Lancet 2024 cited by 243

  19. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

    Authors: Roy S. Herbst, Edward B. Garon, Dong‐Wan Kim, Byoung Chul Cho, José Luis Perez‐Gracia, Ji‐Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin Förster, I. Monnet, Silvia Novello, Zsuzsanna Szalai, Matthew A. Gubens, Wu‐Chou Su, Giovanni Luca Ceresoli, Ayman Samkari, Erin Jensen, Gregory M. Lubiniecki, Paul Baas - Journal of Clinical Oncology 2020 cited by 281

  20. Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

    Authors: Jhanelle E. Gray, Myung‐Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng‐Chih Lin, Yi‐Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam - Clinical Cancer Research 2023 cited by 60

  21. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

    Authors: Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts, Tibor Csőszi, Gyula Ostoros, Z. Mark, Christina S. Baik, Anil A. Joy, C. Chouaïd, Jesus Corral Jaime, Vı́tězslav Kolek, Margarita Majem, Jaromı́r Roubec, Edgardo S. Santos, Anne C. Chiang, Giovanna Speranza, Chandra P. Belani, Alberto Chiappori, Manish R. Patel, Krisztina Czebe, Lauren A. Byers, Brittany Bahamón, Cong Li, Emily Sheldon‐Waniga, Eric Kong, Miguel Williams, Sunita Badola, Hyunjin Shin, Lisa Bedford, Jeffrey Ecsedy, Matthew Bryant, Siân Jones, John K. Simmons, E. Jane Leonard, Claudio Dansky Ullmann, David R. Spigel - Journal of Thoracic Oncology 2019 cited by 147

  22. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Authors: Ross A. Soo, Ji‐Youn Han, Urania Dafni, Byoung Chul Cho, Chong Ming Yeo, Ernest Nadal, Enric Carcereny, J. de Castro, María Ángeles Sala, Reyes Bernabé, Linda Coate, M. Provencio Pulla, Rosario García Campelo, Sinéad Cuffe, Sayed M.S. Hashemi, Martin Früh, Bartomeu Massutí, José García-Sánchez, Manuel Dómine, Margarita Majem, J.M. Sánchez-Torres, Christian Britschgi, Miklos Pless, Georgia Dimopoulou, Heidi Roschitzki‐Voser, Barbara Ruepp, Rafael Rosell, Rolf A. Stahel, Solange Peters, Rolf A. Stahel, Solange Peters, Ross A. Soo, Ji‐Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki‐Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne‐Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki‐Voser, Susanne Roux, Barbara Ruepp, Magdalena Sánchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, M. Reist, Priska Rentsch, Linda Coate, Sinéad Cuffe, Sayed M.S. Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario García Campelo, Bartomeu Massutí, José López García, Manuel Dómine, Margarita Majem, José Miguel Sánchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross A. Soo, Chong Ming Yeo, Ji‐Youn Han, Byoung Chul Cho - Annals of Oncology 2021 cited by 116

  23. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

    Authors: Solange Peters, Jean-Louis Pujol, Urania Dafni, Manuel Dómine, Sanjay Popat, Martin Reck, J. Andrade, A. Becker, Denis Moro‐Sibilot, Alessandra Curioni‐Fontecedro, Olivier Molinier, Kristiaan Nackaerts, A. Insa Mollá, R. Gervais, Guillermo López-Vivanco, J. Madelaine, Julien Mazières, Martin Faehling, Frank Griesinger, Margarita Majem, J.L. González-Larriba, M. Provencio Pulla, Katerina Vervita, Heidi Roschitzki‐Voser, Barbara Ruepp, Paul Mitchell, Rolf A. Stahel, C. Le Péchoux, Dirk De Ruysscher, Rolf A. Stahel, Anita Hiltbrunner, Mariana Pardo-Contreras, A. Gasca-Ruchti, Nino Giacomelli, Roswitha Kammler, Nesa Marti, Rita Pfister, Anne‐Christine Piguet, Susanne Roux, Sandra Troesch, M. Schneider, Robin Schweri, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, S. Tsouprou, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Franck Morin, Elodie Amour, G. Mariaule, N. Archirel, María Dolores Arnaiz Fernández, E. Pereira, M. Fernandez, K. Lopez, Ainhoa Hernández, Sarah Chinchen, H. Jurkovic, Alan S. Livingstone, Jerry W. Mitchell, Macie B. Walker, Paul Mitchell, S. Ng, Christopher Steer, Karen Briscoe, Amina Saqib, Ehtesham Abdi, Baerin Houghton, Kenneth J. O’Byrne, B.R. Chittajallu, Brett Hughes, A. Black, Kristiaan Nackaerts, Henrica M.J. Werner, R. Gervais, Gérard Zalcman, F. Vaylet, P. Merle, I. Monnet, Denis Moro‐Sibilot, Olivier Molinier, Nicolas Girard, P.-J. Souquet, Fabrice Barlési, D. Debieuvre, Hélène Senellart, M. Poudenx, A. Dixmier, Damien Pouessel, Jacques Cadranel, H. Léna, Élisabeth Quoix, S. Friard, Clarisse Audigier-Valette, Julien Mazières, Éric Pichon, Martin Faehling and 20 more - Annals of Oncology 2021 cited by 114

  24. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Authors: Marta Casarrubios, Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García-Campelo, Martín Lázaro-Quintela, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé, Núria Viñolas, Isidoro Barneto Aranda, Bartomeu Massutí, Belén Sierra‐Rodero, Cristina Martínez-Toledo, Ismael Fernández‐Miranda, Roberto Serna‐Blasco, Atocha Romero, Virginia Calvo, Alberto Cruz‐Bermúdez - Journal for ImmunoTherapy of Cancer 2022 cited by 62